Mobile

A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to 70...

Update Il y a 5 ans
Reference: EUCTR2006-004694-97

A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 male and female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are treatment naïve

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The present study is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 and pioglitazone 30mg, compared to placebo, administered as monotherapy over 12 weeks in treatment naïve subjects with Type 2 Diabetes Mellitus.

Inclusion criteria

  • Type 2 diabetes mellitus

Links